Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients by Spinelli, FRANCESCA ROMANA et al.
RESEARCH ARTICLE Open Access
Association between antibodies to
carbamylated proteins and subclinical
atherosclerosis in rheumatoid arthritis
patients
Francesca Romana Spinelli1†, Arbi Pecani1†, Francesco Ciciarello2, Tania Colasanti1, Manuela Di Franco1,
Francesca Miranda1, Fabrizio Conti1, Guido Valesini1 and Cristiano Alessandri1*
Abstract
Background: Rheumatoid arthritis (RA) patients carry a high risk of cardiovascular morbidity and mortality. The
excess of cardiovascular disease cannot be entirely explained by traditional risk factors and the immune system
contributes to the development of atherosclerosis. Moreover, post-translational modifications such as citrullination
and carbamylation have been linked to inflammation and atherosclerosis. Anti-carbamylated proteins antibodies
(anti-CarP) are a new subset of autoantibodies identified in RA patients. This study aimed to investigate a possible
association between anti-CarP and subclinical atherosclerosis in RA patients.
Methods: We enrolled RA patients and normal healthy controls (NHS) without known cardiovascular risk factors or
heart disease. Cardiovascular risk was assessed using the Modified Systemic Coronary Risk Evaluation (mSCORE).
Anti-CarP were investigated by a solid phase “home-made” ELISA. Anti-citrullinated protein antibodies (ACPA) and
Rheumatoid Factor (RF) were investigated by ELISA assays. Subclinical atherosclerosis was evaluated by brachial
artery Flow-Mediated Dilatation (FMD) and Carotid Intima-Media Thickness (c-IMT) while arterial stiffness by Ankle-
Brachial Index (ABI) and Cardio-Ankle Vascular Index (CAVI).
Results: We enrolled 50 RA patients (34 F and 16 M, mean age 58.4 ± 13.1 years, mean disease duration 127 ± 96.
7 months) and 30 age and sex matched NHS. According to the mSCORE, 58% of patients had a low risk, 32% a
moderate and 8% a high risk for cardiovascular disease. FMD was significantly lower in RA patients than in NHS (5.6
± 3.2 vs 10.7 ± 8.1%; p < 0.004) and CAVIs significantly higher in a RA patients compared to NHS (left CAVI 8.9 ± 1.7
vs 8.1 ± 1.5; p < 0.04 for and right CAVI 8.8 ± 1.6 vs 8.0 ± 1.4; p < 0.04 for the). ABI and c-IMT did not differ between
the two populations. The multivariate regression analysis showed a significant association of anti-CarP antibodies
with FMD, left and right CAVI and both c-IMT (r = 1.6 and p = 0.05; r = 1.7 and p = 0.04; r = 2.9 and p = 0.05; r = 1.5
and p = 0.03; r = 1.1 and p = 0.03 respectively).
Conclusions: This study confirms that RA patients, without evidence of cardiovascular disease or traditional risk
factors, have an impaired endothelial function. Moreover, we found an association with anti-CarP antibodies
suggesting a possible contribution of these autoantibodies to endothelial dysfunction, the earliest stage of
atherosclerosis. Besides ultrasound assessment, anti-CarP should be assessed in RA patients and considered an
additional cardiovascular risk factor.
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Background
Rheumatoid arthritis (RA) is a chronic systemic and disab-
ling disease affecting 0.5–1% of the general population.
RA is characterized by the presence of autoantibodies
including rheumatoid. factor (RF) and anti-citrullinated
peptide antibodies (ACPA). RA patients have an increased
risk of morbidity and mortality for cardiovascular (CV)
events as a result of accelerated atherosclerosis [1, 2].
Interestingly, RA and atherosclerosis are both chronic in-
flammatory diseases sharing inflammatory biomarkers as
well as similar pattern of cellular activation consistent
with chronic inflammation [3]. A main role toward the
development of CV disease in RA has been attributed to
inflammation and autoimmunity [4, 5]. Considering the
high incidence of CV events in RA patients, an important
step ahead might be the identification of high-risk individ-
uals that may benefit from treatment in order to prevent
overt CV disease. So far, only ACPA have been implicated
in the development of CV disease in RA [6]. Antibodies
against carbamylated proteins (anti-CarP), an end product
of the chemical reaction leading to homocitrullination,
have been recently identified in the sera of RA patients
showing an important predictive and prognostic value [7].
Moreover, a link between protein carbamylation, inflam-
mation and atherosclerosis has been already demonstrated
[8]. Actually, the most appropriate assessment of CV risk
in RA patients is still a matter of debate. Nowadays, the
Systematic Coronary Risk Evaluation (SCORE) is widely
used in European countries to determine 10-years risk of
CV disease in the general population. The SCORE is
calculated using as input data age, sex, systolic blood pres-
sure, smoking, total cholesterol (tChol) and high density
lipoproteins (HDL) levels of the subject: a SCORE greater
than 5% is associated to a high 10-years risk of CV disease
[9]. Since SCORE include only traditional CV risk factors,
while recent evidence support the role of an additional
CV burden resulting from the inflammatory process in
RA [10], the EULAR task force group drew up a conserva-
tive recommendation to solve this issue suggesting to add
a 1.5 multiplication factor if a RA patient have two of the
following criteria: (I) disease duration longer than 10 years;
(II) positivity for RF or ACPA; (III) presence of extra-
articular manifestations [11]. However, these recommen-
dations derived mostly form mortality studies [11] while
CV disease appears earlier during the course of RA. A
revision of the EULAR recommendations suggested apply-
ing the 1.5 multiplication factor also in RA patients pre-
senting features of metabolic syndrome [12]. This latter
recommendation has not yet undergone validation.
Different noninvasive imaging techniques allow
studying the development of atherosclerosis. In this
regard, ultrasonographic techniques such as flow-
mediated dilatation (FMD) and carotid intima-media
thickness (c-IMT) are considered efficient methods to
assess subclinical atherosclerosis. Abnormal values of FMD,
resulting from endothelial dysfunction, were observed in
both long-standing and early RA patients without clinically
evident CV disease [13–15]. Increased c-IMT together with
the increased incidence of carotid plaques have been
described in RA patients [16]. In addition, asymptomatic
peripheral artery disease and stiffness of the arterial wall are
reported as important markers of atherosclerosis. These
parameters are assessed by noninvasive techniques: Ankle-
Brachial Index (ABI) and the newly developed method of
Cardio Ankle Vascular Index (CAVI) [17, 18].
This study aimed at evaluating the possible associations
between autoantibodies detected in sera of RA patients
(anti-CarP, ACPA and RF) and subclinical atherosclerotic
changes assessed by non-invasive imaging techniques.
Methods
Study population
Consecutive RA patients followed-up at Arthritis Center
of Sapienza University of Rome were invited to enter in
this study. All patients were at least 18 years old and ful-
filled the 2010 ACR/EULAR classification criteria for RA
[19]. Thirty age and sex matched healthy blood donors
were included as controls. A written informed consent
was obtained from all subjects before enrolment. The
protocol was approved by the local Ethical Committee.
Patients having diabetes, hypertension, history of heart
disease, chronic kidney failure or family history of
premature atherosclerosis in first degree relative were
excluded. All patients underwent a detailed clinical
examination including the measurement of height (cm)
and weight (kg) in order to calculate their body mass
index (BMI) and blood pressure. Data regarding smok-
ing habit and medications were registered for all the pa-
tients and controls. Disease activity was measured by the
Disease Activity Score (DAS) 28 (ESR).
Cardiovascular risk assessment
The CV risk was assessed using the Modified Systemic
Coronary Risk Evaluation (mSCORE). The mSCORE
was calculated using validated risk tables for both high
and low risk populations. In the present study, the low
risk table was utilized since Italy has been classified as a
low risk country for cardiovascular disease [20]. Patients
are classified at high risk for CV disease if their 10-years
risk score is >5%.
Blood sampling
In all subjects, blood was drawn in the morning after at
least 10 h fasting. Sera were obtained by centrifugation
and stored at −20 °C until tested. The following laboratory
variables were determined in both groups: erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP), lipid
levels (total, high-density lipoprotein and low density
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lipoprotein cholesterol and triglycerides), RF, ACPA and
anti-CarP.
ELISA assays for autoantibodies detection
Anti-CarP
Anti-CarP antibodies were detected by a modified solid
phase “home-made” ELISA as described by Shi et al.
with few modifications using carbamylated foetal calf
serum (FCS) as antigen [21]. In brief, as we described
previously [22], Nunc Maxisorp plates (Thermo Scien-
tific) were coated overnight at + 4 °C with non-modified
FCS and Ca-FCS (10 μg/ml in carbonate bicarbonate
buffer). After washing plates were blocked with phos-
phate buffered saline (PBS) 1% bovine serum albumin
(BSA) (Sigma) for 6 h at + 4 °C. Subsequently, the wells
were incubated with patients’ serum diluted 1/50 in
PBS/0.05% tween/BSA 1% overnight at + 4 °C. After four
washes, plates were incubated for 2 h at room
temperature (RT) with goat polyclonal antihuman IgG
alkaline phosphatase conjugated antibodies (Sigma) di-
luted at 1:1000 in PBS/0.05% tween/BSA 1%. After four
washes, a solution of paranitrophenyl phosphate tablets
in ethanolamine was used for the enzyme reaction and
the plates were read at a 405 nm wavelength after
30 min at RT. All assays were performed in duplicate
and the absorbance of control wells (unmodified FCS)
was subtracted to account for non-specific binding. The
levels were determined in arbitrary units per milliliter
(AU/ml) using a standard curve. The cut-off for anti-
CarP antibody ELISA was established as the mean plus
three times the standard deviation (SD) of the healthy
control.
Anti-CCP and RF antibody assays
ACPAs were detected using a second-generation ELISA
(anti-CCP) kit (Delta Biologicals, Tucson, AZ, USA)
while IgM RF was determined as part of routine analysis
by immunonephelometry (Behering, Marburg, Germany)
according to the manufacturers’ instructions.
Non-invasive imaging techniques
All subjects were evaluated using FMD after an appro-
priate preparation: adequate information was given to
the patient 1 day prior the examination to limit stress-
induced sympathetic activity on the day of the actual
measurement. All patients were asked to abstain from
vitamin supplementation and medications (especially
those targeting the cardiovascular system) for at least
72 h before the examination while smoking, caffeine or
caffeine-containing drink intake and exercises had been
avoided for 12 h before FMD assessment [23]. Patients
were initially asked to lie quiet for at least 20 min in a
climate controlled room (22–24 °C); blood velocity and
blood pressure were assessed continuously until reaching
the resting state than the brachial artery was scanned in
longitudinal section 2 cm above the elbow, and the
centre of the artery was defined as soon as the clearest
picture of the anterior and posterior intimal layers were
obtained. The transmit zone was set to the depth of the
nearest wall and a volume size measurement spanning
from intima to intima was performed. After measuring
the baseline arterial diameter for around 10 cardiac cy-
cles, an increased blood flow in the artery was induced
by the inflation of an appropriate size sphygmomanometer
cuff placed around the forearm (distal to the ultrasound
probe) at a pressure of 200 mmHg for 5 min, followed by
release [23]. Another measurement was performed 60–90
s after cuff deflation and the diameter of the brachial ar-
tery was measured at the peak of R wave that corresponds
to the end diastole. FMD was calculated as the ratio of the
difference between peak and baseline diameter of the
brachial artery divided by the baseline diameter and
expressed as a percentage of change in vessel calibre;
FMD value was normalised by dividing the percentage of
FMD by shear rate (AUC) [23].
C-IMT was measured by performing an external
carotid ultrasound examination in the common carotid
artery and the detection of focal plaques in the extracra-
nial carotid tree by manual technique using a commer-
cially available scanner equipped with 7–12 MHz linear
transducer as the patient was lying in the supine position
with the neck rotated to the opposite side of examin-
ation. Carotid plaques were counted in each territory.
An IMT between 0.9 and 1.2 was considered thickening
and values exceeding 1.2 mm was considered atheroscler-
otic plaque [24] In our study, CAVI and ABI were evalu-
ated using a VaSera model VS-i 1000 vascular screening
system (Fukuda Deneshi Co.Ltd, Tokyo, Japan). The reli-
ability of VaSera VS-1000 in estimating CAVI and ABI has
been already validated [25]. In brief, CAVI is a new index
that represents stiffness of the aorta, femoral artery and
tibial artery. CAVI is measured from an ECG, phonogram
(PCG), brachial artery waveform and ankle artery wave-
form and calculated using a specific algorithm:
CAVI ¼ α ¼ 2þ=ΔPð Þx ln SBP=DBPð ÞPWV2 þ β
where ΔP is Systolic Blood Pressure (SBP)— Diastolic
Blood Pressure (DBP), þ is blood density and a and b
are constants. Scale conversions constants are deter-
mined so as to match CAVI with Pulse Wave Velocity
(PWV) using Hasegawa method [25]. All measurements
and calculations are made together and automatically in
Va-Sera model (FukudaDeneshiCo.LTD, Tokyo, Japan).
This equation was derived from Bramwell-Hill’s equation
and the stiffness parameter β. CAVI reflects the stiffness
of the aorta, femoral artery and tibial artery as a whole,
and is theoretically not affected by blood pressure [25].
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This device utilises blood pressure cuffs with sensors on
all four limbs to generate plethysmographs. Since patients
were tested for CAVI and ABI in the same day that they
were tested for FMD, they had already refrained from
smoking prior testing considering its potential role as a
vasoconstrictor agent that may influence the result. The
cuffs were placed on bilateral upper and lower extremities
while the subject was in supine position with the limbs at
the same level as the heart, in a comfortable position in a
warm room [25].
Statistical analysis
Kolmogrov-Smirnov test was used to assess the normal
distribution of the data. Values presenting a normal
distribution are expressed as mean ± standard deviation
(SD) while values that were not normally distributed are
expressed as median ± interquartile range (IQR). Student
t-test was applied for numerical variables in order to com-
pare the averages of two separate groups (populations).
Multiple regression analysis was performed using each of
the vascular parameters (FMD, c-IMT, CAVI, ABI) as
dependent variables while RF, ACPA and anti-CarP were
the independent variables. P values < 0.05 were considered
significant. Statistical analysis was performed using SPSS
version 21.0.
Results
Fifty RA patients and 30 NHS were included in the
study. Demographic and clinical characteristics of RA
patients and NHS together with CV risk factors of the
all the study participants are summarised in Table 1.
Thirty-two patients (64%) had a moderate disease activ-
ity (DAS28 ≥ 3.2 < 5.1), while 5 (10%) had a low disease
(DAS28 < 3.2) activity and 9 (18%) were in remission
(DAS28 < 2.6). Only 4 (8%) of the patients included in this
study had a high disease activity (DAS28 ≥ 5.1). Patients
with RA had significantly higher ESR and CRP values than
NHS (Table 1). Anti-CarP, ACPA and RF were positive ex-
clusively in RA patients. Among tradition CV risk factors,
only smoking status and HDL cholesterol levels differed
significantly between patients and controls (Table 1). Con-
cerning concomitant medications, 80% of the patients
were using NSAIDs as needed and 60% of them were tak-
ing glucocorticoids. Most of the patients were treated with
DMARDs: methotrexate (MTX) was the most frequent
DMARD prescribed (in 23 out of 50 RA patients, 46%),
Table 1 Characteristic of Rheumatoid Arthritis patients and Healthy Controls
RA (n = 50) NHS (n = 30) P
Demographics
Age (mean ± SD, yrs) 58.4 + 13.1 56.7 + 16.7 ns
Sex (n, % female) 34 (68.0) 20 (66.6) ns
Inflammatory markers
ESR (mm/h, mean ± IQR) 22.9 + 17.6 10.6 + 9.3 0.000
CRP (mg/L ± IQR) 5.4 + 5.7 2.9 + 1.7 0.000
RA disease characteristics
Disease duration (months, mean ± SD) 127 + 97.6 n.a. n.a.
DAS 28 (mean ± SD) 4.0 + 1.5 n.a. n.a.
ACPA positivity (n, %) 35 (70) 0 (0) 0.000
RF positivity (n, %) 34 (68) 0 (0) 0.000
Anti-CarP positivity (n, %) 19 (38) 0 (0) 0.000
Traditional Cardiovascular risk factors
Smoking, current (n, %) 15 (30) 5 (16.6) 0.002
Systolic blood pressure (mmHg, mean ± SD) 135.5 + 19.5 135.06 + 19.01 ns
Diastolic blood pressure (mmHg, mean ± SD) 84.5 + 10.8 80.5 + 8.91 ns
Total Cholesterol (mg/dl, mean ± SD) 188 + 37.6 186 + 34.6 ns
HDL cholesterol (mg/dl, mean ± SD) 60.06 + 14.25 40.5 + 6.6 0.001
LDL cholesterol (mg/dl, mean ± SD) 117 + 35.5 114 + 32.3 0.02
Triglycerides (mg/dl, mean ± SD) 93.2 + 35.9 93.1 + 35.01 ns
Body Mass Index (kg/m2, mean ± SD) 24.8 + 4.19 25.4 + 4.54 ns
ESR erythrosedimentation rate, CRP C reactive protein, DAS28 Disease Activity Score 28, ACPA anti-citrullinated peptides antibodies, RF Rheumatoid Factor, anti-
CarP anti-carbamylated protein antibodies, HDL high density lipoproteins, LDL low density lipoproteins
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alone or in combination with other conventional or
biological DMARDs.
Cardiovascular risk assessment based on mSCORE
According to the mSCORE, 29 out of the 50 RA patients
included in this study (58%) were classified as having a
low risk for developing CV diseases, 16 (32%) had a
moderate risk and only 4 (8%) had a high risk for CV
disease (Fig. 1a). In the low risk group, 10 (34.4%) were
male and 19 (65.6%) females while in the moderate risk
group 4 (25%) were males and 12 (75%) females. From
the 4 patients classified as having a high risk for CV dis-
eases, 2 (50%) were males and 2 were females (Fig. 1b).
Ultrasonographic assessment of subclinical atherosclerosis
Both basal brachial flow and post-hyperemic flow were
significantly lower in RA patients compared to NHS and
consequently FMD values — after normalisation of the
FMD value by the shear ratio — were as well signifi-
cantly lower in RA patients (Table 2). CAVIs were
significantly higher in RA patients than NHS; neither
c-IMTs nor ABIs differed between the two popula-
tions (Table 2).
The results of the multivariate regression analysis are
summarised in Table 3.
Patients with RA showed a significant association of anti-
CarP positivity with FMD and CAVI; moreover, a positive
association was observed between the presence of anti-CarP
and c-IMT. Differently, ACPA were significantly associ-
ated to ABI and c-IMT. None of the above mentioned vas-
cular parameters showed a significant association with RF.
Discussion
The results of this study demonstrate, for the first time,
an association between anti-CarP antibodies and sub-
clinical atherosclerosis in RA patients. Moreover, the
study confirms an association between ACPA and cIMT
in accordance with previous findings [26, 27].
During the progression of RA, different pathophysio-
logical processes occur and may contribute to athero-
genesis; indeed, cellular and molecular changes leading
initially to endothelial dysfunction and later on to ath-
erosclerosis have been involved also in RA pathogenesis
[28]. In physiological conditions, endothelium prevents
the adhesion of mononuclear cells. Inflammation acti-
vates endothelial cells leading to vascular integrity loss,
a
b
Fig. 1 Stratification of cardiovascular risk based on mSCORE. a Cardiovascular risk in RA patients divided according to different risk categories.
b Gender distribution of cardiovascular risk. mSCORE =modified Systematic Coronary Risk Evaluation, RA = Rheumatoid Arthritis
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increased expression of adhesion molecules (such as
VCAM-1 and ICAM-1) allowing endothelial cells to
participate to the inflammatory response [29]. The in-
creased expression of the adhesion molecules stimulates
the adherence and migration of monocytes to the vessel
wall where these cells further differentiate into macro-
phages by enhancing vessel inflammation. Continuous
endothelial cell activation leads to subsequent endothe-
lial dysfunction that is the first step of atherogenesis and
contribute to the development of overt clinical features
characterizing the later stages of the vascular disease
[30]. The results of our study confirm that RA patients
with a moderate disease activity, without clinical evi-
dence of atherosclerotic disease, have an altered endo-
thelial function assessed by brachial FMD. Inflammation
may interfere with endothelial function through the ef-
fect of proinflammatory cytokines on nitric oxide release
[31, 32]. Large and small artery compliance is also al-
tered in RA patients. Arterial compliance results from
the involvement of arterial media layer; therefore, the
structural regional injury can be a consequence of both
endothelial and smooth muscle cell damage rather than
endothelial damage alone [33]. Among the different
markers of endothelial dysfunction, brachial artery FMD
is an ultrasonographic method useful to investigate sub-
clinical atherosclerosis in autoimmune rheumatic dis-
eases [34, 35]. Interestingly, in our cohort of RA patients
we found a significant association between the presence
of anti-CarP antibodies and brachial FMD; conversely,
neither ACPA nor RF were statistically associated to
brachial FMD. Cardio Ankle Vascular Index has been
recently proposed as a newly developed method for
assessing arterial stiffness and predicting CV risk [36].
Arterial stiffness is mostly regulated by nitric oxide avail-
ability and CAVI, which is an indicator of arterial stiff-
ness, somehow measures even endothelial cell function
[18]. In this study, we found a significant difference in
CAVI between the control group and RA patients. Previ-
ous data reported higher CAVI in patients with RA com-
pared to healthy subjects and a reduction of CAVI after
administration of biologic DMARDs (such as etanercept,
tocilizumab and adalimumab) [37]. When interpreting
the results of our study we considered even the effect
that pharmacological therapies can induce on CAVI:
46% of RA patients in this study were taking DMARDs,
mostly MTX. Published data support the role of MTX in
lowering the CV risk in RA patients suggesting that
treating the inflammation may reduce CV risk [38];
however, data on MTX are not conclusive [39]. In our
cohort, multivariate analysis did not detect any differ-
ence in CAVI levels according to ongoing treatment.
Besides the association between anti-CarP and FMD,
we found a statistically significant association between
anti-CarP antibodies, but again not ACPA nor RF, and
Table 2 Assessment of subclinical atherosclerosis in
Rheumatoid Arthritis patients and Healthy Controls
Vascular Parameters RA (n = 50) NHS (n = 30) P
Flow Mediated Dilatation
(%, mean ± SD)
5.6 ± 3.2 10.7 ± 8.1 0.004
Basal brachial flow (ml/min,
mean ± SD)
18.2 ± 8.4 26.7 ± 8.2 0.001
Post hyperaemic flow (ml/min,
mean ± SD)
32.3 ± 18.4 49.1 ± 15.2 0.001
Cardio Ankle Vascular Index left
(mean ± SD)
8.9 ± 1.7 8.1 ± 1.5 0.04
Cardio Ankle Vascular Index right
(mean ± SD)
8.8 ± 1.6 8.0 ± 1.4 0.04
Ankle Brachial Index left (mean ± SD) 1.1 ± 0.1 1.4 ± 1.6 ns
Ankle Brachial Index right (mean ± SD) 1.1 ± 0.1 1.1 ± 0.1 ns
Carotid Intima Media Thickness
left (mm)
9.8 ± 0.1 0.9 ± 0.2 ns
Carotid plaques left (N, %) 16 (32) 10 (33.3) ns
Carotid Intima Media Thickness
right (mm)
0.9 ± 0.2 0.9 ± 0.2 ns
Carotid plaques right (N, %) 14 (28) 10 (33.3) ns
RA Rheumatoid Arthritis, NHS normal healthy subjects
Table 3 Multivariate analysis showing association between autoantibodies and vascular parameters of subclinical atherosclerosis in
Rheumatoid Arthritis patients
Anti-CarP ACPA RF
R2 P β R2 P β R2 P β
Flow Mediated Dilatation (%, mean ± SD) 0.22 0.01 −0,241 −0.3 ns 0,157 1.7 ns −0.197
Cardio Ankle Vascular Index left 0.2 0.05 −0,258 0.2 ns 0,196 0.3 ns 0.219
Cardio Ankle Vascular Index right 0.2 0.05 −0,258 0.1 ns 0,196 0.3 ns 0.219
Ankle Brachial Index left −0.03 ns 0,175 −0.1 ns 0,139 1.8 ns −0.195
Ankle Brachial Index right −0.1 ns 0,139 0.8 ns 0,139 1.7 ns −0.197
Carotid Intima Media Thickness left (mm) 2.2 0.03 −0,294 3.2 0,02 −0.298 −02 ns 0.220
Carotid Intima Media Thickness right (mm) 2.1 0.03 −0,294 3.1 0.02 −0.298 −0.2 ns 0.220
anti-CarP anti-carbamylated protein antibodies, ACPA anti-citrullinated peptides antibodies, RF Rheumatoid Factor
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CAVI. This is the first study associating anti-CarP posi-
tivity with two indices of endothelial dysfunction — bra-
chial FMD and CAVI — suggesting a possible contribute
of proteins carbamylation in the development of endo-
thelial dysfunction. There are no published data demon-
strating a direct effect of ACPA or RF on endothelial
function; this might explain the evidence of an exclusive
association of anti-CarP with the two surrogate markers
of endothelial dysfunction. Indeed, carbamylation of low
density lipoproteins (LDL) seems to induce endothelial
dysfunction acting via the lectin-type oxidized LDL
receptor 1 (LOX-1), uncoupling NO synthase thus redu-
cing NO availability [40]. We tested anti-CarP using
carbamylated FCS which also contains lipid-associated
proteins; thus, we cannot exclude that anti-CarP can be
at least in part directed to carbamylated-LDL.
Arterial wall thickening and the presence of athero-
sclerotic plaque are markers of subclinical atheroscler-
osis even in RA patients [41]. Carotid-IMT has been
demonstrated to predict the development of cardiovas-
cular events in patients with RA suggesting that high
carotid IMT values should raise the clinical suspicion for
the development of CV complications in these patients
[42, 43]. Carotid-IMT provides important evidence on
CV disease in early RA patients as well as in patients
with long standing disease [43]. We evaluated the c-IMT
in our cohort of RA patients without overt CV disease.
Interestingly, we didn’t find significant differences in c-
IMT between RA patients and control group. When
interpreting this result, we must consider that RA pa-
tients participating in this study showed a low mSCORE
adapted for RA and adjusted for Italian population [20].
There was a small difference in anti-CarP levels between
the patients with low mSCORE when compared with
those with high mSCORE but not with those with mod-
erate mSCORE (p = 0.04 and p = 0.2, respectively). In
our population, we found a significant correlation be-
tween c-IMT and both ACPA and anti-CarP levels.
Published data report an association with ACPA positiv-
ity and risk for CV events in RA [26]. Thus, the data re-
ported in our study are in line with previous findings
but, for the first time, extend the association of c-IMT
to a new subset of autoantibodies (i.e. anti-CarP). More-
over, we found a significant association between ACPA
positivity and ABI, a simple and high sensitive and spe-
cific method to investigate the peripheral arterial disease
(PAD) [44]. Smoking has been considered as the most
prevalent atherosclerotic risk factor in ABI positive pa-
tients [45]. On the other hand, smoking has been closely
related to ACPA positive RA subsets [46]. Therefore, all
the above facts support the possible association between
ACPA positivity and ABI that we report for the first time
through this study. Interestingly, only ACPA was associ-
ated to ABI nor anti-CarP; this evidence further suggests
the different role and pathogenic mechanisms of these
autoantibodies have, supporting again the fact that
ACPA and anti-CarP are two distinct antibodies subset
that do not cross react with each other with different
roles in the pathogenesis of both RA and atherogenesis.
This study has some limitations. The first issue is the
number of patients enrolled: to make the results more
robust a larger cohort should be evaluated although
finding a lot of RA patients without CV risk factors and/
or CV disease is a serious challenge. Moreover, the test
applied to detect anti-CarP used FCS as antigen, not
allowing to determine which antigen specificity is actu-
ally responsible for the effect on endothelial cells.
Conclusions
Rheumatoid Arthritis patients with a moderate disease ac-
tivity without clinical evidence of atherosclerotic disease or
traditional cardiovascular risk factors have an altered endo-
thelial function that indicates a high probability toward the
development of an atherosclerotic disease. The findings of
this study reinforce the observed link between RA and
atherosclerosis and further emphasize the crucial role of
the prolonged inflammatory state as a promoter of cardio-
vascular disease in RA [47]. The association between sero-
logical markers of RA and the surrogate markers of
subclinical atherosclerosis may suggest a stratification of
CV risk based on patient’s serology; indeed, the presence of
anti-CarP antibodies was associated with brachial FMD,
CAVI and c-IMT. Taking into account all the findings of
this study, an important step ahead might be the investiga-
tion of the role of anti-CarP antibodies with in vitro studies
which might clarify their potential role on endothelial cells
activation and damage.
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EULAR: European league against rheumatism; FCS: Foetal calf serum;
FMD: Flow mediated dilatation; HDL: High density lipoprotein;
ICAM: Intercellular adhesion molecule 1; IQR: Interquartile range; LDL: Low
density lipoprotein; LOX-1: Lectin-type oxidized LDL receptor 1;
mSCORE: Modified systemic coronary risk evaluation; MTX: Methotrexate;
NHS: Normal healthy subject; PBS: Phosphate buffered saline; PWV: Pulse-
wave velocity; RA: Rrheumatoid arthritis; RF: Rheumatoid factor; RT: Room
temperature; SBP: Systolic blood pressure; SD: Standard deviation;
VCAM1: Vascular cell adhesion molecule 1
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